AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Century Therapeutics Inc (NASDAQ:IPSC)
2.13 USD
-0.070 3.182%Sponsored Reports
Loading...
| Previous Close (in USD) | 2.2 |
|---|---|
| Change | -0.070 3.182% |
| 52 W H/L (in USD) | 5.510/1.280 |
| EBITDA (in USD) | -111.047M |
| PE Ratio | -- |
| Volume | 1899291 |
| Diluted Eps TTM | -2.43 |
| Total Assets (in USD) | 360.691M |
|---|---|
| Total Liabilities (in USD) | 175.941M |
| Revenue TTM (in USD) | 1.37M |
| Cash (in USD) | 47.324M |
| Market Cap (in USD) | 274.483 M |
| Revenue Per Share TTM | 0.023 |
| Gross Profit TTM (in USD) | 5.199M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Employees: 152
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Osvaldo Flores Ph.D. | Pres, CEO & Director | 1963 |
| 2. | Dr. Adrienne Farid Ph.D. | Chief Operations Officer | 1962 |
| 3. | Dr. Luis Borges | Chief Scientific Officer | 1962 |
| 4. | Mr. Douglas Carr CPA | VP of Fin. and Operations & Sec. | NA |
| 5. | Dr. Gregory Russotti Ph.D. | Chief Technology Officer | 1967 |
| 6. | Mr. Kenneth J. Dow J.D. | Head of Legal & Compliance | NA |
| 7. | Dr. Shane Williams Ph.D. | Chief People Officer | NA |
| 8. | Dr. Michael C. Diem | Chief Bus. Officer | 1971 |
| 9. | Dr. Hyam I. Levitsky M.D. | Pres of R&D | 1958 |
| 10. | Mr. Mark Wallet | Head of Immunology & VP | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.790 1.806% | 44.05 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.694 1.570% | 43.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+5.090 1.152% | 445.605 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+6.720 1.069% | 632.26 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2016 |
|---|---|---|---|---|---|
| Income Before Tax | -130.841M | -95.781M | -53.575M | -244.769M | - |
| Minority Interest | - | - | - | - | - |
| Net Income | -130.932M | -95.824M | -54.66M | -245.979M | - |
| Selling General Administrative | 31.857M | 19.235M | 9.495M | 5.767M | 81.392M |
| Gross Profit | 5.199M | - | - | - | 2.483M |
| Reconciled Depreciation | 8.44M | 3.748M | 1.402M | 0.249M | - |
| Ebit | -133.831M | -94.883M | -53.898M | -245.979M | - |
| Ebitda | -121.296M | -94.506M | -47.07M | -18.574M | - |
| Depreciation And Amortization | 12.535M | 0.377M | 6.828M | 227.405M | - |
| Operating Income | -133.831M | -94.883M | -53.898M | -245.979M | - |
| Other Operating Expenses | 139.03M | 94.883M | 49.176M | 20.033M | - |
| Interest Expense | 1.105M | 1.275M | 0.381M | 0M | 0M |
| Tax Provision | 0.091M | 0.043M | - | - | - |
| Interest Income | - | - | - | - | - |
| Net Interest Income | -1.404M | -1.275M | -0.381M | 0M | - |
| Income Tax Expense | 0.091M | 0.043M | 1.085M | 1.21M | - |
| Total Revenue | 5.199M | 0M | 0M | 0M | 470.319M |
| Total Operating Expenses | 139.03M | 94.883M | 49.176M | 20.033M | - |
| Cost Of Revenue | - | - | - | - | 467.836M |
| Total Other Income Expense Net | 2.99M | -0.898M | 0.323M | 1.21M | - |
| Net Income From Continuing Ops | -130.932M | -95.824M | -53.575M | -244.769M | - |
| Net Income Applicable To Common Shares | -130.932M | -95.824M | -53.575M | -244.769M | - |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 360.691M | 486.544M | 437.375M | 106.776M | 90.896M |
| Intangible Assets | - | - | - | 9.392M | - |
| Other Current Assets | 3.591M | 3.443M | 5.275M | 0.256M | 0.124M |
| Total Liab | 175.941M | 183.806M | 41.137M | 213.188M | 182.755M |
| Total Stockholder Equity | 184.75M | 302.738M | 396.238M | -106.412M | -91.859M |
| Other Current Liab | 9.22M | 10.232M | 1.082M | 0.052M | 1.446M |
| Common Stock | 0.006M | 0.006M | 0.005M | 0.001M | 0.001M |
| Capital Stock | 0.006M | 0.006M | 0.005M | 0.001M | 0.001M |
| Retained Earnings | -655.771M | -519.098M | -388.166M | -292.342M | -238.767M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 3.239M | 3.486M | 2.149M | 0.206M |
| Cash | 47.324M | 84.265M | 56.445M | 27.211M | 44.064M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 17.846M | 29.817M | 15.655M | 12.112M | 2.994M |
| Current Deferred Revenue | 4.372M | 7.154M | 5.323M | 3.738M | - |
| Net Debt | 0.847M | -34.851M | -32.983M | -5.656M | -44.064M |
| Short Term Debt | 1.513M | 6.977M | 1.654M | 0.24M | - |
| Short Long Term Debt | - | 6.502M | 1.039M | - | - |
| Short Long Term Debt Total | 48.171M | 49.414M | 23.462M | 21.555M | - |
| Other Stockholder Equity | 840.407M | 824.292M | 785.049M | 185.932M | 146.91M |
| Property Plant Equipment | - | 82.785M | 57.967M | 24.777M | 2.488M |
| Total Current Assets | 176.994M | 319.721M | 228.154M | 78.797M | 84.122M |
| Long Term Investments | 89.096M | 51.854M | 135.914M | 1.053M | 4.08M |
| Short Term Investments | 125.414M | 231.233M | 166.434M | 48.542M | 37.475M |
| Net Receivables | 0.665M | 0.78M | 0.25M | 0.908M | 0.123M |
| Long Term Debt | - | 3.739M | 8.903M | 9.679M | - |
| Inventory | - | - | -0.25M | 1.88M | 2.336M |
| Accounts Payable | 2.741M | 5.454M | 7.596M | 8.082M | 1.548M |
| Accumulated Other Comprehensive Income | 0.108M | -2.462M | -0.65M | -0.003M | -0.003M |
| Non Currrent Assets Other | 0.541M | 3.239M | 3.486M | 1.24M | 0.206M |
| Non Current Assets Total | 183.697M | 166.823M | 209.221M | 27.979M | 6.774M |
| Capital Lease Obligations | 48.171M | 39.173M | 14.559M | 11.919M | 0M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2016 |
|---|---|---|---|---|---|
| Investments | 17.476M | -253.368M | -8.21M | -41.54M | - |
| Total Cashflows From Investing Activities | -13.128M | -298.338M | -22.757M | -19.834M | - |
| Total Cash From Financing Activities | 27.158M | 417.774M | 47.69M | 74.839M | 98.094M |
| Net Income | -130.932M | -95.824M | -53.575M | -244.769M | - |
| Change In Cash | 28.082M | 30.434M | -16.336M | 38.837M | - |
| Begin Period Cash Flow | 58.162M | 27.728M | 44.064M | 31.424M | - |
| End Period Cash Flow | 86.244M | 58.162M | 27.728M | 70.261M | 31.424M |
| Total Cash From Operating Activities | 14.052M | -89.002M | -41.269M | -16.168M | - |
| Depreciation | 8.44M | 3.748M | 1.402M | 0.249M | - |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | 78.326M |
| Sale Purchase Of Stock | 27.158M | 223.92M | - | - | - |
| Other Cashflows From Financing Activities | -13.128M | 196.159M | 47.69M | -19.834M | - |
| Capital Expenditures | 30.604M | 44.97M | 9.825M | 2.46M | 11.124M |
| Change In Working Capital | 123.945M | -2.797M | 4.862M | 2.259M | - |
| Other Non Cash Items | 1.93M | 1.209M | 0.444M | 225.946M | - |
| Free Cash Flow | -16.552M | -133.972M | -51.094M | -18.628M | - |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Growth Compy Commingled Pl O | 2 years ago | 1600920 |
| 2. | Fidelity Growth Company Fund | 2 years ago | 1042379 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 628424 |
| 4. | Fidelity Growth Company K6 | 2 years ago | 553755 |
| 5. | iShares Russell 2000 ETF | 2 years ago | 535191 |
| 6. | Federated Hermes Kaufmann Small Cap A | 2 years ago | 338980 |
| 7. | Federated Hermes Kaufmann Small Cap Grow | 2 years ago | 338980 |
| 8. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 299597 |
| 9. | Federated Hermes Kaufmann Growth | 2 years ago | 267745 |
| 10. | Federated Hermes Kaufmann R | 2 years ago | 267745 |
| 11. | Fidelity Small Cap Index | 2 years ago | 241876 |
| 12. | iShares Russell 2000 Value ETF | 2 years ago | 223230 |
| 13. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 165434 |
| 14. | Fidelity Series Growth Company | 2 years ago | 161300 |
| 15. | Fidelity Extended Market Index | 2 years ago | 123271 |
| 16. | Bridgeway Ultra-Small Company Market | 2 years ago | 103800 |
| 17. | Schwab US Small-Cap ETF™ | 2 years ago | 98959 |
| 18. | Vanguard Russell 2000 ETF | 2 years ago | 87526 |
| 19. | State St Russell Sm Cap® Indx SL Cl I | 2 years ago | 86467 |
| 20. | Vanguard Health Care ETF | 2 years ago | 70574 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 2 years ago | 3612551 |
| 2. | Casdin Capital, LLC | 2 years ago | 3206380 |
| 3. | Boxer Capital LLC | 2 years ago | 1750000 |
| 4. | BlackRock Inc | 2 years ago | 1518996 |
| 5. | Dafna Capital Management LLC | 2 years ago | 1307407 |
| 6. | Avidity Partners Management LP | 2 years ago | 1221555 |
| 7. | Vanguard Group Inc | 2 years ago | 1138653 |
| 8. | Baker Bros Advisors LP | 2 years ago | 797460 |
| 9. | Federated Hermes Inc | 2 years ago | 618482 |
| 10. | Octagon Capital Advisors LP | 2 years ago | 540000 |
| 11. | Geode Capital Management, LLC | 2 years ago | 468457 |
| 12. | State Street Corporation | 2 years ago | 448491 |
| 13. | Millennium Management LLC | 2 years ago | 357401 |
| 14. | Jacobs Levy Equity Management, Inc. | 2 years ago | 293941 |
| 15. | Morgan Stanley - Brokerage Accounts | 2 years ago | 279928 |
| 16. | Northern Trust Corp | 2 years ago | 185979 |
| 17. | Charles Schwab Investment Management Inc | 2 years ago | 152051 |
| 18. | Bridgeway Capital Management, LLC | 2 years ago | 120100 |
| 19. | Renaissance Technologies Corp | 2 years ago | 119200 |
| 20. | Bank of New York Mellon Corp | 2 years ago | 90556 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...